Friday, October 30, 2026

Hewlett Stock Plummets 9% At Opening Bell Wednesday, Trailing Market

ViaNews Editorial Team

August 30, 2023

Hewlett Stock Plummets 9% At Opening Bell Wednesday, Trailing Market

(VIANEWS) - Hewlett-Packard Company (NYSE: HPQ) shares experienced a sharp 9.18% drop, to EUR28.49 at 10:05 EST on Wednesday morning. This decline came after five consecutive sessions where HPQ shares had experienced upward momentum; overall market trends remain positive however; the NYSE Index rose 1.02% to EUR16,041.49 this week, making this its third straight session of growth. Hewlett Packard Enterprise Company saw its share price decrease 7.46% since reaching its 52-week high of EUR33.90; yet, Hewlett remains a key player in the tech industry.

About Hewlett

HP Inc. is a globally renowned technology company providing a diverse selection of personal computing, imaging, printing and related technologies, solutions and services. Operating through three segments - Personal Systems, Printing and Corporate Investments - HP serves individual consumers, small-and medium-sized businesses and large enterprises such as those found within government, health and education sectors. Established in 1939 and located in Palo Alto California.

Yearly Analysis

Hewlett's stock is currently trading at EUR28.49, well below its 52-week high of EUR33.90 and may therefore be undervalued at present. Additionally, anticipated sales growth is negative 19.7% for this year but 2.4% is predicted for next year - suggesting possible undervaluation at present. Hewlett Packard's EBITDA of 32.05. suggests the company is producing an healthy profit margin; however, given their negative sales growth and uncertainty surrounding their future plans it may represent a risky investment to certain investors. Overall, investors should carefully consider both current market conditions and financial performance of Hewlett Packard before making investment decisions. Conducting additional research or analysis may help investors assess both its potential risks and rewards when considering Hewlett stock as an investment option.

Technical Analysis

Hewlett Packard Enterprise Company's (HEW) stock price has experienced downward pressure lately, falling significantly below both its 50-day moving average of EUR31.75 and 200-day moving average of EUR29.75 - this indicates a downward trend both short- and long-term. Furthermore, its trading volume of 5,749,436 represents 17.59% less than its average volume of 6,977,100; suggesting there may be less investor enthusiasm in its stock. However, the stock's volatility has been relatively low over the past week, month, and quarter, with an average intraday variation of 0.43%, -0.16%, and 1.17% in each case respectively. While its highest amplitude of average volatility was 0.87% during these timeframes it has remained relatively steady throughout this quarter. Hewlett Packard stock is currently classified as oversold (=20), suggesting it could be undervalued and poised for an upward price rebound. Investors should exercise caution and conduct thorough research prior to making any investment decisions.

Quarter Analysis

Hewlett Packard Enterprise Stock Performance Analysis. Hewlett's sales growth estimates for both ongoing and subsequent quarters show negative values, signaling revenue decline. Furthermore, growth estimates for next quarter are positive while ongoing quarter's estimate shows negative growth indicating potential shortfall in performance in near term. A year-on-year quarterly revenue growth of 21.7% is alarming as it indicates that revenue has been decreasing year after year due to factors like competition, market changes or internal issues. Overall, Hewlett Packard's negative sales growth and declining revenue growth indicates it may not be an attractive investment opportunity at this time. Investors may wish to investigate other companies with better growth potential before making any investment decisions.

Equity Analysis

Hewlett appears to be an asset-rich company with a low PE ratio and good dividend yield; estimated forward annual dividend rates of 1.05 and an estimated forward annual dividend yield of 3.4% indicate the company is providing stable income streams to shareholders. However, its trailing twelve month earnings per share (EPS) of EUR2.67 may not meet investors' expectations and its PE ratio of 10.67 suggests it may not be underpriced as they might hope. Overall, Hewlett seems like a safe and sound investment option; however, investors should first evaluate their personal goals and risk tolerance prior to making any decisions. Furthermore, it would be worthwhile for investors to examine additional financial metrics or company-specific factors before making their final decision.

More news about Hewlett (HPQ).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com